Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard L Fu

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
BMC Nephrology|April 24, 2021
Practice variation in the treatment of patients with renal hyperparathyroidism: a survey-based study in the NetherlandsJaimie L H Zhang, Natasha M Appelman-Dijkstra, Edouard L Fu, et al.
BMJ (Clinical Research Ed.)|June 26, 2024
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort studyEdouard L Fu, Deborah J Wexler, Sara J Cromer, et al.
Clinical Kidney Journal|July 5, 2021
Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study designMarco Trevisan, Edouard L Fu, Yang Xu, et al.
Clinical Kidney Journal|December 17, 2024
Impact of arteriovenous fistula formation on trajectory of kidney function decline: a target trial emulationLuis Loureiro Harrison, Edouard L Fu, Peter C Thomson, et al.
Circulation|February 24, 2026
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial EmulationYang Xu, Tao Huang, Yue Zhang, et al.
Journal of Nephrology|December 2, 2022
Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) projectJim Alkas, Alessandro Bosi, Arvid Sjölander, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 14, 2023
Long-term Visit-to-Visit Variability in Hemoglobin A<sub>1c</sub> and Kidney-Related Outcomes in Persons With DiabetesYang Xu, Shujie Dong, Edouard L Fu, et al.
American Heart Journal|October 5, 2021
Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomesYang Xu, Edouard L Fu, Marco Trevisan, et al.
Clinical Kidney Journal|November 2, 2023
The long-term benefits of early intensive therapy in chronic diseases-the legacy effectCarmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, et al.
American Heart Journal|August 6, 2019
High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patientsEdouard L Fu, Mikael Andersson Franko, Achim Obergfell, et al.
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
BMC Nephrology|April 24, 2021
Practice variation in the treatment of patients with renal hyperparathyroidism: a survey-based study in the NetherlandsJaimie L H Zhang, Natasha M Appelman-Dijkstra, Edouard L Fu, et al.
BMJ (Clinical Research Ed.)|June 26, 2024
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort studyEdouard L Fu, Deborah J Wexler, Sara J Cromer, et al.
Clinical Kidney Journal|July 5, 2021
Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study designMarco Trevisan, Edouard L Fu, Yang Xu, et al.
Clinical Kidney Journal|December 17, 2024
Impact of arteriovenous fistula formation on trajectory of kidney function decline: a target trial emulationLuis Loureiro Harrison, Edouard L Fu, Peter C Thomson, et al.
Circulation|February 24, 2026
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial EmulationYang Xu, Tao Huang, Yue Zhang, et al.
Journal of Nephrology|December 2, 2022
Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) projectJim Alkas, Alessandro Bosi, Arvid Sjölander, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 14, 2023
Long-term Visit-to-Visit Variability in Hemoglobin A<sub>1c</sub> and Kidney-Related Outcomes in Persons With DiabetesYang Xu, Shujie Dong, Edouard L Fu, et al.
American Heart Journal|October 5, 2021
Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomesYang Xu, Edouard L Fu, Marco Trevisan, et al.
Clinical Kidney Journal|November 2, 2023
The long-term benefits of early intensive therapy in chronic diseases-the legacy effectCarmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, et al.
American Heart Journal|August 6, 2019
High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patientsEdouard L Fu, Mikael Andersson Franko, Achim Obergfell, et al.
Pageof 8